China Healthcare Stocks Slip as Licensing Oversight Tightens; Big Pharma Deals Continue
China's healthcare sector fell 1.3% this week amid stepped-up scrutiny of licensing arrangements from regulators in both the U.S. and China. The group trails the Hang Seng Index year-to-date, while certain subsectors and deal activity — including a major Innovent-Pfizer collaboration and supply contracts for WuXi Bio — drove selective gains.